Advanced Glycation End Product Blocker Drugs Have a Great Potential to Prevent Diabetic Cardiomyopathy in an Animal Model of Diabetes Mellitus Type-2
Introduction. Sphingosine 1 phosphate (S1P) is a product of the sphingosine kinase 1 (SphK1) enzyme. Increased S1P can lead to tissue fibrosis that is also one of the pathways for developing diabetic cardiomyopathy. Advanced glycation end products (AGEs) increase S1P in cells. The study is aimed at...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Cardiovascular Therapeutics |
| Online Access: | http://dx.doi.org/10.1155/2022/7014680 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850224087423516672 |
|---|---|
| author | Amir Hossein Heydari Mojtaba Fathi Sophia Heydari Mohammad Esmaeil Heidari |
| author_facet | Amir Hossein Heydari Mojtaba Fathi Sophia Heydari Mohammad Esmaeil Heidari |
| author_sort | Amir Hossein Heydari |
| collection | DOAJ |
| description | Introduction. Sphingosine 1 phosphate (S1P) is a product of the sphingosine kinase 1 (SphK1) enzyme. Increased S1P can lead to tissue fibrosis that is also one of the pathways for developing diabetic cardiomyopathy. Advanced glycation end products (AGEs) increase S1P in cells. The study is aimed at using aminoguanidine (AG) as an AGEs blocker drug to prevent diabetic cardiomyopathy. Materials and methods. 210 rats were enrolled in the study. Diabetes mellitus type-2 was induced, and rats were divided into AG treated diabetic and nondiabetic groups. The heart histology was assessed with Masson’s trichrome and hematoxylin-eosin staining. Cardiac function was measured with transthoracic echocardiography. S1P level and SphK1 gene expression were measured by western-blot and RT-qPCR, respectively. Results. Results showed that S1P level increases in diabetes, and its augmentation in cardiac tissue with K6PC-5 leads to cardiac fibrosis. 50 and 200 mg/kg of AG prevented cardiac fibrosis, but 100 mg/kg had no significant preventive effect. AG suppressed the SphK1 gene expression and reduced the fibrotic effect of S1P. AG preserved cardiac function by keeping ejection fraction and fractional shortening within the normal range in diabetic rats. Conclusion. AG has a suppressor effect on SphK1 gene expression besides its AGEs blocker role. AG is a potential drug to use in diabetic patients for preventing the development of diabetic cardiomyopathy. Other drugs that have AGEs or S1P blocker effects are a good choice for diabetic cardiomyopathy prevention. |
| format | Article |
| id | doaj-art-5c082b4fa3304e84a418ba1c87e87bc4 |
| institution | OA Journals |
| issn | 1755-5922 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cardiovascular Therapeutics |
| spelling | doaj-art-5c082b4fa3304e84a418ba1c87e87bc42025-08-20T02:05:43ZengWileyCardiovascular Therapeutics1755-59222022-01-01202210.1155/2022/7014680Advanced Glycation End Product Blocker Drugs Have a Great Potential to Prevent Diabetic Cardiomyopathy in an Animal Model of Diabetes Mellitus Type-2Amir Hossein Heydari0Mojtaba Fathi1Sophia Heydari2Mohammad Esmaeil Heidari3School of MedicineBiochemistry DepartmentShahid Beheshti HospitalDepartment of Electrical EngineeringIntroduction. Sphingosine 1 phosphate (S1P) is a product of the sphingosine kinase 1 (SphK1) enzyme. Increased S1P can lead to tissue fibrosis that is also one of the pathways for developing diabetic cardiomyopathy. Advanced glycation end products (AGEs) increase S1P in cells. The study is aimed at using aminoguanidine (AG) as an AGEs blocker drug to prevent diabetic cardiomyopathy. Materials and methods. 210 rats were enrolled in the study. Diabetes mellitus type-2 was induced, and rats were divided into AG treated diabetic and nondiabetic groups. The heart histology was assessed with Masson’s trichrome and hematoxylin-eosin staining. Cardiac function was measured with transthoracic echocardiography. S1P level and SphK1 gene expression were measured by western-blot and RT-qPCR, respectively. Results. Results showed that S1P level increases in diabetes, and its augmentation in cardiac tissue with K6PC-5 leads to cardiac fibrosis. 50 and 200 mg/kg of AG prevented cardiac fibrosis, but 100 mg/kg had no significant preventive effect. AG suppressed the SphK1 gene expression and reduced the fibrotic effect of S1P. AG preserved cardiac function by keeping ejection fraction and fractional shortening within the normal range in diabetic rats. Conclusion. AG has a suppressor effect on SphK1 gene expression besides its AGEs blocker role. AG is a potential drug to use in diabetic patients for preventing the development of diabetic cardiomyopathy. Other drugs that have AGEs or S1P blocker effects are a good choice for diabetic cardiomyopathy prevention.http://dx.doi.org/10.1155/2022/7014680 |
| spellingShingle | Amir Hossein Heydari Mojtaba Fathi Sophia Heydari Mohammad Esmaeil Heidari Advanced Glycation End Product Blocker Drugs Have a Great Potential to Prevent Diabetic Cardiomyopathy in an Animal Model of Diabetes Mellitus Type-2 Cardiovascular Therapeutics |
| title | Advanced Glycation End Product Blocker Drugs Have a Great Potential to Prevent Diabetic Cardiomyopathy in an Animal Model of Diabetes Mellitus Type-2 |
| title_full | Advanced Glycation End Product Blocker Drugs Have a Great Potential to Prevent Diabetic Cardiomyopathy in an Animal Model of Diabetes Mellitus Type-2 |
| title_fullStr | Advanced Glycation End Product Blocker Drugs Have a Great Potential to Prevent Diabetic Cardiomyopathy in an Animal Model of Diabetes Mellitus Type-2 |
| title_full_unstemmed | Advanced Glycation End Product Blocker Drugs Have a Great Potential to Prevent Diabetic Cardiomyopathy in an Animal Model of Diabetes Mellitus Type-2 |
| title_short | Advanced Glycation End Product Blocker Drugs Have a Great Potential to Prevent Diabetic Cardiomyopathy in an Animal Model of Diabetes Mellitus Type-2 |
| title_sort | advanced glycation end product blocker drugs have a great potential to prevent diabetic cardiomyopathy in an animal model of diabetes mellitus type 2 |
| url | http://dx.doi.org/10.1155/2022/7014680 |
| work_keys_str_mv | AT amirhosseinheydari advancedglycationendproductblockerdrugshaveagreatpotentialtopreventdiabeticcardiomyopathyinananimalmodelofdiabetesmellitustype2 AT mojtabafathi advancedglycationendproductblockerdrugshaveagreatpotentialtopreventdiabeticcardiomyopathyinananimalmodelofdiabetesmellitustype2 AT sophiaheydari advancedglycationendproductblockerdrugshaveagreatpotentialtopreventdiabeticcardiomyopathyinananimalmodelofdiabetesmellitustype2 AT mohammadesmaeilheidari advancedglycationendproductblockerdrugshaveagreatpotentialtopreventdiabeticcardiomyopathyinananimalmodelofdiabetesmellitustype2 |